Argenes Initiates Phase I Clinical Study of ARG098 (anti-Fas IgM monoclonal antibody), a Novel Therapeutics for Rheumatoid Arthritis, in Europe

Published: Oct 05, 2007

Tokyo, Oct 5, 2007 (JCN Newswire) - Argenes, Inc. announce today that it has started Phase I clinical study of the novel anti-rheumatoid arthritis (RA) agent ARG098 in patients with RA in Belgium and has administered to the first patient. The clinical study intends to evaluate the safety and tolerability of ARG098 into the knee joint cavity of patients with RA and examine its efficacy and pharmacokinetics.

Back to news